$MXCT News
Last published 1d ago
- 1d agoMXCTMAXCYTE THIRD QUARTER EARNINGS CONFERENCE CALL - MAXCYTE INCEarnings Call TranscriptsThank you for standing by and welcome to the MaxSight third quarter earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and
- 1d agoMXCTMAXCYTE, INC. - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 1.01 Item 2.02 Item 3.02 Item 7.01 Item 9.01
- 1d agoMXCTMaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue GuidanceGlobeNewswireThird Quarter and Recent Business Highlights: Reports total revenue of $10.2 million for the third quarter of 2026, including $8.2 million of core revenue and $2.0 million of SPL Program-related revenueRaises Full Year
- 1d agoMXCTMaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue GuidanceGlobeNewswireMaxCyte will host its third quarter 2026 earnings call today, November 10th, at 8:30 a.m. Eastern Time
- 1d agoMXCTMaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue BaseGlobeNewswireROCKVILLE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has entered into a definitive agreement to acquire Akron BioProducts LLC (“Akron” or “Akron Bio”) from affiliates of Arcli ...
- 1d agoMXCTMaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue BaseGlobeNewswireAkron Bio is a leading supplier of GMP-grade reagents and ancillary materialsExpands MaxCyte’s footprint across the cell therapy manufacturing workflow and establishes a combined portfolio supporting five commercially
- 2w agoMXCTMaxCyte to Participate in Three Upcoming Investor ConferencesGlobeNewswireROCKVILLE, Md., Oct. 28, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization
- 4w agoMXCTMaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue GuidanceGlobeNewswireROCKVILLE, Md., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization
- 2mo agoMXCTMaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireROCKVILLE, Md., Sept. 11, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and
- 2mo agoMXCTMaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapiesGlobeNewswireROCKVILLE, Md., Aug. 19, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and
- 3mo agoMXCTMaxCyte Reports Second Quarter 2026 Financial ResultsGlobeNewswireReports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue Reiterates Full Year 2026 GuidanceRepurchased approximately
- 3mo agoMXCTMaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy DevelopmentGlobeNewswireROCKVILLE, Md., July 21, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization
- 3mo agoMXCTMaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026GlobeNewswireROCKVILLE, Md., July 15, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and
- 6mo agoMXCTMaxCyte First Quarter Earnings Conference CallMAXCYTE INCEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the MagSight First Quarter Earnings Conference Call. At this time, all participants are on the listen-only mode. After the speaker's presentation, there will be a questi
- 6mo agoMXCTMaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 GuidanceGlobeNewswireFirst quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenue Reiterates 2026 revenue guidance of $30-32 million; with Core revenue of $25-27
- 6mo agoMXCTMaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026GlobeNewswireROCKVILLE, Md., April 29, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and
- 7mo agoMXCTMaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireROCKVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and
- 7mo agoMXCTMaxCyte Fourth Quarter Earnings Conference CallMAXCYTE INCEarnings Call TranscriptsGood day, everyone, and welcome to MaxSight's fourth quarter earnings conference call. At this time, all participants are in a listen-only mode. After the presentation, there will be a question-and-answer session. To par
- 7mo agoMXCTMaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 GuidanceGlobeNewswireFourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary announcement
- 7mo agoMXCTMaxCyte Appoints Parmeet Ahuja as Chief Financial OfficerGlobeNewswireROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and
- 8mo agoMXCTMaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discoveryGlobeNewswireROCKVILLE, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and
- 8mo agoMXCTMaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026GlobeNewswireROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and
- 10mo agoMXCTMaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireROCKVILLE, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and
- 11mo agoMXCTCellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPOBusiness WireIndustry veteran brings two decades of platform commercialization experience in cell therapy, bioprocessing, and bioanalytics as Cellares prepares to support multiple clinical trials in 2026 Appointment follows five
- 12mo agoMXCTMaxCyte Announces Planned CFO Transition in 2026GlobeNewswireROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and
- 12mo agoMXCTMaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue GuidanceGlobeNewswireROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and
- 1y agoMXCTMaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue GuidanceGlobeNewswireMaxCyte will now host its earnings conference call on November 12, 2025 Management will present at the Stifel Healthcare Conference on November 11, 2025 and Stephens Investment Conference on November 19, 2025
- 1y agoMXCTMaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025GlobeNewswireROCKVILLE, Md., Oct. 08, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and
- 1y agoMXCTMaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid TumorsGlobeNewswireROCKVILLE, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of
- 1y agoMXCTMaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to ProfitabilityGlobeNewswireROCKVILLE, Md., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and
- 1y agoMXCTMaxCyte, Inc. (MXCT) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoMXCTMaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 GuidanceGlobeNewswireROCKVILLE, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and
- 1y agoMXCTMaxCyte Signs Platform License Agreement with Adicet BioGlobeNewswireMaxCyte's Flow Electroporation® technology and ExPERT™ platform to support development of Adicet's gamma delta T cell therapy gene edited programs ROCKVILLE, Md., Aug. 04, 2025 (GLOBE NEWSWIRE) -- MaxCyte,
- 1y agoMXCTMaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy PipelineGlobeNewswireROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and
- 1y agoMXCTMaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular TherapiesGlobeNewswireROCKVILLE, Md. and LONDON, June 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery,
- 1y agoMXCTMaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 GuidanceGlobeNewswireROCKVILLE, Md., May 07, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and
- 1y agoMXCTMaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025GlobeNewswireROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development
- 1y agoMXCTMaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 GuidanceGlobeNewswireROCKVILLE, Md., March 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development
- 1y agoMXCTMaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics ProgramsGlobeNewswireROCKVILLE, Md., Feb. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and
- 1y agoMXCTMaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor ConferenceGlobeNewswireROCKVILLE, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and
- 1y agoMXCTMaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing AssessmentsGlobeNewswireROCKVILLE, Md., Jan. 30, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of
- 1y agoMXCTMaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireROCKVILLE, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and
- 1y agoMXCTMaxCyte Announces Retirement of Board Member Art MandellGlobeNewswireROCKVILLE, Md., Dec. 22, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and
- 1y agoMXCTMaxCyte Announces Streamlined Operations and Raises 2024 Revenue GuidanceGlobeNewswireROCKVILLE, Md., Dec. 08, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and
- 1y agoMXCTMaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based TherapeuticsGlobeNewswireROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and
- 2y agoMXCTMaxCyte, Inc. (MXCT) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoMXCTMaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 GuidanceGlobeNewswireROCKVILLE, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and
- 2y agoMXCTMaxCyte to Participate in Two Upcoming Investor ConferencesGlobeNewswireROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and
- 2y agoMXCTMaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024GlobeNewswireROCKVILLE, Md., Oct. 11, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and
- 2y agoMXCTMaxCyte Appoints Ali Soleymannezhad as Chief Commercial OfficerGlobeNewswireROCKVILLE, Md., Oct. 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and